The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis

• Published in: Biochemical and biophysical research communications Vol. 454; no. 2; pp. 262 - 268
• Main Authors: Magnus, Nathalie, Meehan, Brian, Garnier, Delphine, Hashemi, Maryam, Montermini, Laura, Lee, Tae Hoon, Milsom, Chloe, Pawlinski, Rafal, Ohlfest, John, Anderson, G. Mark, Mackman, Nigel, Rak, Janusz
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.11.2014
• Subjects: Adolescent; Adult; Animals; Brain - metabolism; Brain - pathology; Brain Neoplasms - diagnosis; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Brain tumor; Cancer; Cell Line, Tumor; EGFR; Gene Deletion; Gene Expression Regulation, Neoplastic; Glioblastoma - diagnosis; Glioblastoma - genetics; Glioblastoma - metabolism; Glioblastoma - pathology; Glioma - diagnosis; Glioma - genetics; Glioma - metabolism; Glioma - pathology; Humans; Mice; Mice, SCID; Oncogene; Oncogenes; Prognosis; RAS; Receptor, Epidermal Growth Factor - metabolism; Simian virus 40; Thromboplastin - genetics; Thromboplastin - metabolism; Tissue factor; RAS; VTE; Oncogene; Tissue factor; PAR (1–4); SCID; EGFR; Brain tumor; TF; GBM; EGFRvIII; PAI-1; Cancer
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2014.10.041

•Human gliomas are heterogeneous for expression of the procoagulant tissue factor protein.•Tissue factor inhibition delays progression of brain tumors driven by oncogenic EGFR or RAS.•Tissue factor expressed by host cells differently affects subcutaneous and intracranial tumor growth. Glioblastoma multiforme (GBM) is an aggressive form of glial brain tumors, associated with angiogenesis, thrombosis, and upregulation of tissue factor (TF), the key cellular trigger of coagulation and signaling. Since TF is upregulated by oncogenic mutations occurring in different subsets of human brain tumors we investigated whether TF contributes to tumourigenesis driven by oncogenic activation of EGFR (EGFRvIII) and RAS pathways in the brain. Here we show that TF expression correlates with poor prognosis in glioma, but not in GBM. In situ, the TF protein expression is heterogeneously expressed in adult and pediatric gliomas. GBM cells harboring EGFRvIII (U373vIII) grow aggressively as xenografts in SCID mice and their progression is delayed by administration of monoclonal antibodies blocking coagulant (CNTO 859) and signaling (10H10) effects of TF in vivo. Mice in which TF gene is disrupted in the neuroectodermal lineage exhibit delayed progression of spontaneous brain tumors driven by oncogenic N-ras and SV40 large T antigen (SV40LT) expressed under the control of sleeping beauty transposase. Reduced host TF levels in low-TF/SCID hypomorphic mice mitigated growth of glioma subcutaneously but not in the brain. Thus, we suggest that tumor-associated TF may serve as therapeutic target in the context of oncogene-driven disease progression in a subset of glioma.